Avascent is a leading advisor to aerospace industry
stakeholders including OEMs, suppliers, services firms and
institutional investors.
During the past twelve months our team has supported seven sales processes in the space, four of which have closed successfully.
In our recent assignment to investigate the Class C
market, Avascent spoke with over 60 senior executives,
managers and investors in the space to gain perspective on
the market trajectory and key challenges.
On October 20, 2011, the Centers for Medicare and Medicaid Services (CMS) released its final rule governing the Medicare Shared Savings Program (MSSP) for Accountable Care Organizations (ACOs). The final rule features significant changes made in response to over 1,320 comments the agency received following the release of the proposed rule published on March 31, 2011. The final rule is expected to spur heightened overall interest in the transition from traditional Medicare fee-for-service to models of accountable care.
Among the provisions in the Affordable Care Act, the creation of Accountable
Care Organizations (ACOs) stands out as having perhaps the greatest potential
for transforming the healthcare industry.
Recent efforts at earmark reform raise a number of strategic questions for federal contractors and challenge them to create a more balanced portfolio of external and internal funding streams. What hard questions should firms that have benefited from earmarks be asking as they prepare for coming change?
In 2009, a long-awaited moderation in defense
spending began in earnest, coinciding
with a redirection of defense priorities away
from expenditure-heavy platform acquisition
and enhancement. A market that is steady
but not growing creates a new reality with
which corporations serving the defense community
will cope for some time to come. For
companies primarily focused on aerospace
and defense (A&D) in particular, this begs
the critical strategic question: How do we
hold our own, or even sustain growth, in a
down cycle?